利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.031 秒)

    Techniques for producing site-directed mutagenesis of cloned DNA
    1.
    发明授权
    Techniques for producing site-directed mutagenesis of cloned DNA 失效
    用于产生克隆DNA定点诱变的技术

    公开(公告)号：US5284760A

    公开(公告)日：1994-02-08

    申请号：US764085

    申请日：1991-09-23

    申请人： Stephen M. Feinstone ,  Czeslaw Wychowski ,  Jonathan E. Silver ,  Suzanne U. Emerson

    发明人： Stephen M. Feinstone ,  Czeslaw Wychowski ,  Jonathan E. Silver ,  Suzanne U. Emerson

    IPC分类号： C07K14/10 ,  C07K14/105 ,  C12Q1/68 ,  C12N15/10

    CPC分类号： C12Q1/6858 ,  C07K14/005 ,  C12Q1/6853 ,  C07K2319/00 ,  C12N2770/32434 ,  C12N2770/32622

    摘要： A method is described whereby new cDNA or RNA sequences can be introduced into or substituted for cDNA in any chosen position without specific sequence requirements using the polymerase chain reaction (PCR). The method entails the use of primers which are complementary to the 3' and 5' ends of the desired sequence to be inserted as well as to the 3' and 5' ends of the chosen site of insertion in the acceptor molecule. The desired sequence is amplified by PCR such that single stranded fragments are produced. The single stranded fragment of the desired sequence is then annealed to a single stranded acceptor molecule at the site of insertion and extended to produce a double stranded molecule. The double stranded molecule is then separated into two strands which are identical except that one of the strands contains the desired sequence inserted at the chosen site. A second double stranded molecule is then generated.

    摘要翻译： 描述了一种方法，其中可以使用聚合酶链式反应（PCR）将新的cDNA或RNA序列引入任何选定位置或用任何特定序列要求代替cDNA。 该方法需要使用与待插入的所需序列的3'和5'末端互补的引物以及在受体分子中所选插入位点的3'和5'末端。 通过PCR扩增所需的序列，从而产生单链片段。 然后将所需序列的单链片段在插入位点退火至单链受体分子并延伸以产生双链分子。 然后将双链分子分成两条相同的链，除了一条链含有插入所选位点的所需序列外。 然后产生第二双链分子。

    Modified HCV peptide immunogens
    3.
    发明授权
    Modified HCV peptide immunogens 失效
    改良的HCV肽免疫原

    公开(公告)号：US07341726B2

    公开(公告)日：2008-03-11

    申请号：US11429670

    申请日：2006-05-05

    申请人： Jay A. Berzofsky ,  Pablo Sarobe ,  Stephen M. Feinstone ,  Marian E. Major

    发明人： Jay A. Berzofsky ,  Pablo Sarobe ,  Stephen M. Feinstone ,  Marian E. Major

    IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  C07H21/04 ,  C12N15/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55538 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/24143 ,  C12N2770/24222 ,  C12N2770/24234

    摘要： Provided are an isolated peptide having the amino acid sequence DLMGYIPAV (SEQ ID NO: 1), an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139, an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2, and a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence of SEQ ID NO:1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. Further provided are methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

    摘要翻译： 提供了具有氨基酸序列DLMGYIPAV（SEQ ID NO：1）的分离的肽，在氨基酸位置139包含L> A取代的分离的HCV核心多肽，具有SEQ ID NO：1的氨基酸序列的分离的HCV核心多肽 NO：2和HCV核心多肽的片段，其具有比整个HCV核心多肽更少的氨基酸并且包含SEQ ID NO：1的氨基酸序列。 还提供了编码本发明的肽和多肽的核酸，包含本发明的核酸的载体和包含本发明的载体和核酸的细胞。 还提供了在受试者中产生免疫应答和/或治疗或预防受试者的HCV感染的方法，包括向受试者或受试者的细胞施用本发明的任何组合物。

    Modified HCV peptide vaccines
    7.
    发明授权
    Modified HCV peptide vaccines 失效
    改良的HCV肽疫苗

    公开(公告)号：US06685944B1

    公开(公告)日：2004-02-03

    申请号：US09763260

    申请日：2001-10-19

    申请人： Jay A. Berzofsky ,  C. David Pendleton ,  Stephen M. Feinstone ,  Marian E. Major ,  Pablo Sarobe

    发明人： Jay A. Berzofsky ,  C. David Pendleton ,  Stephen M. Feinstone ,  Marian E. Major ,  Pablo Sarobe

    IPC分类号： A61K3929

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/55522 ,  A61K2039/55538 ,  A61K2039/55566 ,  A61K2039/57 ,  C12N2710/24143 ,  C12N2770/24222 ,  C12N2770/24234

    摘要： The present invention provides 1) an isolated peptide having the amino acid sequence DLMGYIPAV, (SEQ ID NO: 1); 2) an isolated HCV core polypeptide comprising an L→A substitution at amino acid position 139; 3) an isolated HCV core polypeptide having the amino acid sequence of SEQ ID NO: 2; and 4) a fragment of an HCV core polypeptide having fewer amino acids than the entire HCV core polypeptide and comprising the amino acid sequence SEQ ID NO: 1. Also provided are nucleic acids which encode the peptides and polypeptides of this invention, vectors comprising the nucleic acids of this invention and cells comprising the vectors and nucleic acids of this invention. The present invention further provides methods of producing an immune response in a subject and/or treating or preventing HCV infection in a subject, comprising administering to the subject, or to a cell of the subject, any of the compositions of this invention.

    摘要翻译： 本发明提供1）具有氨基酸序列DLMGYIPAV（SEQ ID NO：1）的分离肽; 2）在氨基酸位置139包含L> A取代的分离的HCV核心多肽; 3）具有SEQ ID NO：2的氨基酸序列的分离的HCV核心多肽; 和4）具有比整个HCV核心多肽更少的氨基酸并且包含氨基酸序列SEQ ID NO：1的HCV核心多肽的片段。还提供编码本发明的肽和多肽的核酸，其包含 本发明的核酸和包含本发明的载体和核酸的细胞。 本发明进一步提供了在受试者中产生免疫应答和/或治疗或预防受试者的HCV感染的方法，其包括对受试者或受试者的细胞施用任何本发明的组合物。

    Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
    8.
    发明授权
    Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells 失效
    鉴定刺激丙型肝炎病毒特异性细胞毒性T细胞的肽

    公开(公告)号：US5980899A

    公开(公告)日：1999-11-09

    申请号：US894063

    申请日：1992-06-10

    申请人： Jay A. Berzofsky ,  Mutsunori Shirai ,  Toshitaka Akatsuka ,  Stephen M. Feinstone

    发明人： Jay A. Berzofsky ,  Mutsunori Shirai ,  Toshitaka Akatsuka ,  Stephen M. Feinstone

    IPC分类号： G01N33/53 ,  A61K38/00 ,  A61K39/00 ,  A61K39/29 ,  A61P31/12 ,  A61P37/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/18 ,  G01N33/569 ,  G01N33/576 ,  A61K39/12 ,  C07K2/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2770/24222

    摘要： The cytotoxic T cell response to the protein encoded by the NS5 region of hepatitis C virus was determined using 28 peptides from NS5 which were selected by an amphipathicity algorithm as candidates for T cell epitopes. In BALB/c mice, a single relatively conserved epitope represented by a 16-residue synthetic peptide was presented by D.sup.d class I major histocompatibility complex (MHC) molecules to conventional CD4.sup.- CD8.sup.+ CTL. An exemplary peptide, which represents amino acid residues 2422-2437 of the polyprotein of the Chiron HCV1 isolate, had the amino acid sequence MSYSWTGALVTPCAAE [SEQ ID NO: 1]. A CTL line specific for this peptide recognized the two known natural variants of this NS5 sequence, each with conservative substitutions. Thus, CTL can recognize the product of the HCV NS5 gene, the probable RNA polymerase, in association with class I MHC molecules on model target cells and may recognize the same epitope on hepatocytes or any other cells infected with the virus.

    摘要翻译： 使用来自NS5的28个肽来确定由丙型肝炎病毒的NS5区编码的蛋白质的细胞毒性T细胞应答，其通过两亲性算法选择作为T细胞表位的候选物。 在BALB / c小鼠中，通过Dd I类主要组织相容性复合物（MHC）分子向常规CD4-CD8 + CTL提供了由16个残基合成肽表示的单个相对保守的表位。 表示Chiron HCV1分离物的多蛋白的氨基酸残基2422-2437的示例性肽具有氨基酸序列MSYSWTGALVTPCAAE [SEQ ID NO：1]。 该肽特异的CTL系识别了NS5序列的两个已知天然变体，每个具有保守取代。 因此，CTL可以识别HCV NS5基因（可能的RNA聚合酶）与模型靶细胞上的I类MHC分子相关联的产物，并且可以识别肝细胞或感染病毒的任何其它细胞上的相同表位。

    Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus
    9.
    发明授权
    Utilizing a halohydrocarbon containing dissolved water to inactivate a lipid virus 失效
    利用含有溶解水的卤代烃来灭活脂质病毒

    公开(公告)号：US4615886A

    公开(公告)日：1986-10-07

    申请号：US611752

    申请日：1984-05-18

    申请人： Robert H. Purcell ,  Stephen M. Feinstone

    发明人： Robert H. Purcell ,  Stephen M. Feinstone

    IPC分类号： A61L2/00 ,  A61K35/14

    CPC分类号： A61L2/0088

    摘要： A method of inactivating a lipid virus contained in a dry protein carrier by contacting said virus-containing protein carrier for an abbreviated period of time at from 4.degree.-40.degree. C. with a composition including a halohydrocarbon treating agent and water dissolved in said treating agent. Preferred lipid viruses are Hepatitis B virus (HBV) and non-A, non-B Hepatitis (NANBH) virus.

    摘要翻译： 一种使干燥蛋白质载体中含有的脂质病毒灭活的方法，该方法是将含有病毒的蛋白质载体在4°-40℃的缩短时间段内与包含卤代烃处理剂和溶解在所述处理中的水的组合物接触来灭活 代理商 优选的脂质病毒是乙型肝炎病毒（HBV）和非A型非乙型肝炎病毒（NANBH）。